Engineered immune cells show promise against tough lymphoma

NCT ID NCT02601313

Completed Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many patients achieved a response, offering hope for those who have run out of standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brexucabtagene autoleucel (KTE-X19) CAR T cells
What this could lead to: If successful, this could provide a powerful treatment option for patients with hard-to-treat mantle cell lymphoma, potentially leading to long-term remission.
What could go wrong: This is a phase 2 trial with a relatively small number of participants. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems. Not all patients responded, and long-term durability is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Academisch Medisch Centrum

Amsterdam, Netherlands
Banner MD Anderson

Gilbert, Arizona, 85234, United States
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
Centre Hospitalier Universitaire (CHU)

Bordeaux, France
City of Hope

Duarte, California, 91010, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Erasmus Medical Center

Rotterdam, Netherlands
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
H Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Hopital Haut-Leveque

Pessac, 44035, France
Hospital Saint Louis

Paris, 75010, France
Loyola University Chicago

Maywood, Illinois, 60153, United States
Ohio State University

Columbus, Ohio, 43210, United States
Robert W. Franz Cancer Research Center

Portland, Oregon, 97213, United States
Sarah Cannon

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Stanford University

Stanford, California, 94305, United States
Swedish Cancer Institute

Seattle, Washington, 98104, United States
Universitaetsklinikum Wuerzburg

Würzburg, 97080, Germany
University California Los Angeles (UCLA)

Santa Monica, California, 90404, United States
University Medical Center Groningen

Groningen, Netherlands
University of Chicago

Chicago, Illinois, 60637, United States
University of Miami

Miami, Florida, 33136, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Universitätsklinik Dresden

Dresden, 01307, Germany
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.